View Future GrowthMacrogen 過去の業績過去 基準チェック /16Macrogenの収益は年間平均-6%の割合で減少していますが、 Life Sciences業界の収益は年間 減少しています。収益は年間3.1% 8%割合で 増加しています。 Macrogenの自己資本利益率は1.3%であり、純利益率は1.9%です。主要情報-6.04%収益成長率-6.48%EPS成長率Life Sciences 業界の成長53.72%収益成長率7.99%株主資本利益率1.28%ネット・マージン1.91%前回の決算情報31 Mar 2026最近の業績更新分析記事 • Apr 03There May Be Underlying Issues With The Quality Of Macrogen's (KOSDAQ:038290) EarningsMacrogen, Inc. ( KOSDAQ:038290 ) announced strong profits, but the stock was stagnant. We did some digging, and we...分析記事 • Apr 02Macrogen's (KOSDAQ:038290) Sluggish Earnings Might Be Just The Beginning Of Its ProblemsThe subdued market reaction suggests that Macrogen, Inc.'s ( KOSDAQ:038290 ) recent earnings didn't contain any...すべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Jun 15Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩13,920, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 31x in the Life Sciences industry in Asia. Total loss to shareholders of 25% over the past three years.New Risk • May 20New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩148.2b (US$98.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩148.2b market cap, or US$98.4m).分析記事 • Apr 03There May Be Underlying Issues With The Quality Of Macrogen's (KOSDAQ:038290) EarningsMacrogen, Inc. ( KOSDAQ:038290 ) announced strong profits, but the stock was stagnant. We did some digging, and we...お知らせ • Feb 26Macrogen, Inc., Annual General Meeting, Mar 31, 2026Macrogen, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 238, teheran-ro, gangnam-gu, seoul South Korea分析記事 • Dec 22Fewer Investors Than Expected Jumping On Macrogen, Inc. (KOSDAQ:038290)You may think that with a price-to-sales (or "P/S") ratio of 1.1x Macrogen, Inc. ( KOSDAQ:038290 ) is definitely a...Upcoming Dividend • Dec 22Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 23 April 2026. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (12%).分析記事 • Nov 09Macrogen's (KOSDAQ:038290) Dividend Will Be ₩300.00Macrogen, Inc. ( KOSDAQ:038290 ) has announced that it will pay a dividend of ₩300.00 per share on the 23rd of April...Declared Dividend • Nov 08Dividend of ₩300 announcedDividend of ₩300 is the same as last year. Ex-date: 29th December 2025 Payment date: 23rd April 2026 Dividend yield will be 2.0%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has not increased over the past 5 years but payments have been stable during that time.お知らせ • Nov 07Macrogen, Inc. announces Annual dividend, payable on April 23, 2026Macrogen, Inc. announced Annual dividend of KRW 300.0000 per share payable on April 23, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.分析記事 • Mar 19Calculating The Intrinsic Value Of Macrogen, Inc. (KOSDAQ:038290)Key Insights The projected fair value for Macrogen is ₩15,809 based on 2 Stage Free Cash Flow to Equity Current share...お知らせ • Feb 27Macrogen, Inc., Annual General Meeting, Mar 31, 2025Macrogen, Inc., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 238, teheran-ro, gangnam-gu, seoul South KoreaUpcoming Dividend • Dec 20Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 25 April 2025. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.8%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.0%).お知らせ • Dec 11Macrogen, Inc. (KOSDAQ:A038290) agreed to acquire an additional 17.44% stake in Psomagen, Inc. (KOSDAQ:A950200) for KRW 13.5 billion.Macrogen, Inc. (KOSDAQ:A038290) agreed to acquire an additional 17.44% stake in Psomagen, Inc. (KOSDAQ:A950200) for KRW 13.5 billion on December 9, 2024. A cash consideration of KRW 13.54 billion will be paid by Macrogen for 3,355,338 shares. Upon completion, Macrogen, Inc. will own 54.25% stake in Psomagen, Inc. The expected completion of the transaction is December 26, 2024.New Risk • Dec 08New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended March 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company.分析記事 • Nov 13Macrogen, Inc.'s (KOSDAQ:038290) Low P/S No Reason For ExcitementMacrogen, Inc.'s ( KOSDAQ:038290 ) price-to-sales (or "P/S") ratio of 1.2x might make it look like a strong buy right...分析記事 • Jul 24Macrogen, Inc.'s (KOSDAQ:038290) Revenues Are Not Doing Enough For Some InvestorsMacrogen, Inc.'s ( KOSDAQ:038290 ) price-to-sales (or "P/S") ratio of 1.8x might make it look like a strong buy right...New Risk • Jul 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risk Share price has been volatile over the past 3 months (8.2% average weekly change).Upcoming Dividend • Dec 20Upcoming dividend of ₩300 per share at 1.4% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 22 April 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.4%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (0.9%).New Risk • Nov 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 61% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.4% average weekly change).New Risk • Oct 10New major risk - Revenue and earnings growthEarnings have declined by 61% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 61% per year over the past 5 years.Buying Opportunity • Jul 10Now 21% undervaluedOver the last 90 days, the stock is up 5.9%. The fair value is estimated to be ₩28,610, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company became loss making.New Risk • Jun 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change).Buying Opportunity • Apr 10Now 20% undervaluedOver the last 90 days, the stock is up 2.7%. The fair value is estimated to be ₩26,056, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company became loss making.Major Estimate Revision • Mar 30Consensus EPS estimates increase by 30%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from ₩151.0m to ₩158.0m. EPS estimate increased from ₩819 to ₩1,065 per share. Net income forecast to grow 398% next year vs 36% growth forecast for Life Sciences industry in South Korea. Consensus price target of ₩30,000 unchanged from last update. Share price rose 3.5% to ₩20,300 over the past week.Upcoming Dividend • Dec 21Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 24 April 2023. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (0.7%).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Oct 22Macrogen, Inc. (KOSDAQ:A038290) announces an Equity Buyback for KRW 3,000 million worth of its shares.Macrogen, Inc. (KOSDAQ:A038290) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its shares pursuant to a trust contract with Samsung Securities Co., Ltd. The purpose of the share repurchase program is to stabilize the share price and increase shareholders value. The share repurchase program will continue until October 20, 2023. As of October 20, 2022, the company had 722,395 shares in treasury within scope available for dividend and had 1,851 shares in treasury through other repurchase.Price Target Changed • Oct 14Price target decreased to ₩30,000Down from ₩40,000, the current price target is provided by 1 analyst. New target price is 68% above last closing price of ₩17,850. Stock is down 39% over the past year. The company is forecast to post earnings per share of ₩859 for next year compared to ₩114 last year.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Upcoming Dividend • Dec 22Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 25 April 2022. The company is not currently making a profit but it is cash flow positive. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.3%).分析記事 • Apr 02Macrogen's (KOSDAQ:038290) Sluggish Earnings Might Be Just The Beginning Of Its ProblemsThe subdued market reaction suggests that Macrogen, Inc.'s ( KOSDAQ:038290 ) recent earnings didn't contain any...分析記事 • Mar 03Macrogen (KOSDAQ:038290) Has Debt But No Earnings; Should You Worry?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Feb 18New 90-day high: ₩30,650The company is up 8.0% from its price of ₩28,400 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 2.0% over the same period.Is New 90 Day High Low • Jan 18New 90-day low: ₩25,450The company is down 12% from its price of ₩28,800 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 15% over the same period.分析記事 • Jan 09Reflecting on Macrogen's (KOSDAQ:038290) Share Price Returns Over The Last Three YearsFor many investors, the main point of stock picking is to generate higher returns than the overall market. But if you...Is New 90 Day High Low • Dec 23New 90-day low: ₩25,800The company is down 14% from its price of ₩29,900 on 24 September 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 14% over the same period.Is New 90 Day High Low • Oct 15New 90-day low: ₩29,500The company is down 8.0% from its price of ₩31,900 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 1.0% over the same period.お知らせ • Sep 24Macrogen Signs Export Agreement with LG InternationalMacrogen has established the first "Smart Mobile Lab" in Korea and has supplied it to Indonesia as well. Macrogen signed its first export agreement with LG International, on September 22nd. The initial two export units will be supplied to Indonesia through LG International. Following the first agreement, additional units are currently in last-minute negotiation over additional export agreements. Macrogen's Smart Mobile Lab is the mobile container type for on-site COVID 19 testing developed in Korea. It offers one-stop COVID-19 testing within a matter of minutes and it can be easily installed wherever as necessary. Macrogen has designed the SML that is easy to move and install in order to supply the K-quarantine packaging to overseas that are suffering from COVID-19 testing because of insufficient healthcare quarantine infrastructure. SML with strict Bio Safety Level-2(BSL-2) deals with all stages from viral RNA extraction, real-time polymerase chain reaction (RT-PCR), diagnosis, analysis, and to results. It also provides unique and differentiated services for Standard Operating Procedures (SOP), online/on-site training for lab technicians, and instrument maintenance. Macrogen's SML also displays excellent performance in terms of sustainability as it can be extended into a process capable of molecular diagnostic testing for various infectious diseases other than COVID-19. Currently, Macrogen is in the course of preparation for related patent applications based on the unique design structure of SML and the implementation of differentiated additional features.収支内訳Macrogen の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSDAQ:A038290 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費31 Mar 26199,5993,81259,5284,11731 Dec 25195,2682,03059,3904,11730 Sep 25179,980-70057,1433,83830 Jun 25163,919-6,33953,6743,83831 Mar 25145,097-7,76348,1153,83831 Dec 24135,777-7,60344,7923,83830 Sep 24131,729-21,73044,5534,54630 Jun 24131,018-20,52643,9364,54631 Mar 24131,009-20,39543,1984,54631 Dec 23132,803-16,81440,7984,54630 Sep 23133,923-22,28640,9774,26730 Jun 23137,180-18,77841,3514,26731 Mar 23136,765-20,89240,5634,26731 Dec 22138,617-22,25340,0894,26730 Sep 22137,8502,25741,5234,10130 Jun 22130,77587237,4144,10131 Mar 22130,2684,21234,8874,10131 Dec 21129,1751,11232,6334,10130 Sep 21125,233-12,32127,4176,24430 Jun 21123,9621,29926,0966,24431 Mar 21118,03721325,6536,24431 Dec 20112,6034,26726,0226,24430 Sep 2095,78719,62721,9336,18330 Jun 2098,4834,34123,9536,18331 Mar 20101,85210,52723,5966,18331 Dec 19102,81517,89223,4256,18330 Sep 19120,20812,05926,8106,67930 Jun 19115,15012,48825,8086,67931 Mar 19115,6399,10426,3696,67931 Dec 18112,8312,64525,3416,67930 Sep 18108,57512,55026,5925,18830 Jun 18107,95913,22824,9145,18831 Mar 18104,46214,17324,4575,18831 Dec 17101,7939,52923,6205,18830 Sep 1798,4721,66123,1164,93030 Jun 1794,772-55821,6624,93031 Mar 1792,395620,8364,93031 Dec 1691,1134,30120,0814,93030 Sep 1688,2077,04917,6914,17830 Jun 1690,66311,89517,8774,17831 Mar 1687,03011,50816,7774,17831 Dec 1579,53410,17216,5224,17830 Sep 1573,9264,74618,4823,385質の高い収益: A038290には₩1.3B } という大きな 一回限りの 利益があり、過去 12 か月の財務実績が31st March, 2026に影響を及ぼしています。利益率の向上: A038290過去に利益を上げました。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A038290の収益は過去 5 年間で年間6%減少しました。成長の加速: A038290は昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。収益対業界: A038290昨年収益を上げたため、昨年の収益成長をLife Sciences業界 ( -26.7% ) と比較することは困難です。株主資本利益率高いROE: A038290の 自己資本利益率 ( 1.3% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/12 22:26終値2026/07/10 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Macrogen, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Song-hyeop HanDaishin Securities Co. Ltd.Sang-Hun LeeiM SecuritiesJaehoon ChoiKorea Investment & Securities Co., Ltd.2 その他のアナリストを表示
分析記事 • Apr 03There May Be Underlying Issues With The Quality Of Macrogen's (KOSDAQ:038290) EarningsMacrogen, Inc. ( KOSDAQ:038290 ) announced strong profits, but the stock was stagnant. We did some digging, and we...
分析記事 • Apr 02Macrogen's (KOSDAQ:038290) Sluggish Earnings Might Be Just The Beginning Of Its ProblemsThe subdued market reaction suggests that Macrogen, Inc.'s ( KOSDAQ:038290 ) recent earnings didn't contain any...
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩13,920, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 31x in the Life Sciences industry in Asia. Total loss to shareholders of 25% over the past three years.
New Risk • May 20New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩148.2b (US$98.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩148.2b market cap, or US$98.4m).
分析記事 • Apr 03There May Be Underlying Issues With The Quality Of Macrogen's (KOSDAQ:038290) EarningsMacrogen, Inc. ( KOSDAQ:038290 ) announced strong profits, but the stock was stagnant. We did some digging, and we...
お知らせ • Feb 26Macrogen, Inc., Annual General Meeting, Mar 31, 2026Macrogen, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 238, teheran-ro, gangnam-gu, seoul South Korea
分析記事 • Dec 22Fewer Investors Than Expected Jumping On Macrogen, Inc. (KOSDAQ:038290)You may think that with a price-to-sales (or "P/S") ratio of 1.1x Macrogen, Inc. ( KOSDAQ:038290 ) is definitely a...
Upcoming Dividend • Dec 22Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 23 April 2026. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (12%).
分析記事 • Nov 09Macrogen's (KOSDAQ:038290) Dividend Will Be ₩300.00Macrogen, Inc. ( KOSDAQ:038290 ) has announced that it will pay a dividend of ₩300.00 per share on the 23rd of April...
Declared Dividend • Nov 08Dividend of ₩300 announcedDividend of ₩300 is the same as last year. Ex-date: 29th December 2025 Payment date: 23rd April 2026 Dividend yield will be 2.0%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has not increased over the past 5 years but payments have been stable during that time.
お知らせ • Nov 07Macrogen, Inc. announces Annual dividend, payable on April 23, 2026Macrogen, Inc. announced Annual dividend of KRW 300.0000 per share payable on April 23, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
分析記事 • Mar 19Calculating The Intrinsic Value Of Macrogen, Inc. (KOSDAQ:038290)Key Insights The projected fair value for Macrogen is ₩15,809 based on 2 Stage Free Cash Flow to Equity Current share...
お知らせ • Feb 27Macrogen, Inc., Annual General Meeting, Mar 31, 2025Macrogen, Inc., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 238, teheran-ro, gangnam-gu, seoul South Korea
Upcoming Dividend • Dec 20Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 25 April 2025. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.8%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.0%).
お知らせ • Dec 11Macrogen, Inc. (KOSDAQ:A038290) agreed to acquire an additional 17.44% stake in Psomagen, Inc. (KOSDAQ:A950200) for KRW 13.5 billion.Macrogen, Inc. (KOSDAQ:A038290) agreed to acquire an additional 17.44% stake in Psomagen, Inc. (KOSDAQ:A950200) for KRW 13.5 billion on December 9, 2024. A cash consideration of KRW 13.54 billion will be paid by Macrogen for 3,355,338 shares. Upon completion, Macrogen, Inc. will own 54.25% stake in Psomagen, Inc. The expected completion of the transaction is December 26, 2024.
New Risk • Dec 08New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended March 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company.
分析記事 • Nov 13Macrogen, Inc.'s (KOSDAQ:038290) Low P/S No Reason For ExcitementMacrogen, Inc.'s ( KOSDAQ:038290 ) price-to-sales (or "P/S") ratio of 1.2x might make it look like a strong buy right...
分析記事 • Jul 24Macrogen, Inc.'s (KOSDAQ:038290) Revenues Are Not Doing Enough For Some InvestorsMacrogen, Inc.'s ( KOSDAQ:038290 ) price-to-sales (or "P/S") ratio of 1.8x might make it look like a strong buy right...
New Risk • Jul 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risk Share price has been volatile over the past 3 months (8.2% average weekly change).
Upcoming Dividend • Dec 20Upcoming dividend of ₩300 per share at 1.4% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 22 April 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.4%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (0.9%).
New Risk • Nov 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 61% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.4% average weekly change).
New Risk • Oct 10New major risk - Revenue and earnings growthEarnings have declined by 61% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 61% per year over the past 5 years.
Buying Opportunity • Jul 10Now 21% undervaluedOver the last 90 days, the stock is up 5.9%. The fair value is estimated to be ₩28,610, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company became loss making.
New Risk • Jun 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change).
Buying Opportunity • Apr 10Now 20% undervaluedOver the last 90 days, the stock is up 2.7%. The fair value is estimated to be ₩26,056, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company became loss making.
Major Estimate Revision • Mar 30Consensus EPS estimates increase by 30%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from ₩151.0m to ₩158.0m. EPS estimate increased from ₩819 to ₩1,065 per share. Net income forecast to grow 398% next year vs 36% growth forecast for Life Sciences industry in South Korea. Consensus price target of ₩30,000 unchanged from last update. Share price rose 3.5% to ₩20,300 over the past week.
Upcoming Dividend • Dec 21Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 24 April 2023. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (0.7%).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Oct 22Macrogen, Inc. (KOSDAQ:A038290) announces an Equity Buyback for KRW 3,000 million worth of its shares.Macrogen, Inc. (KOSDAQ:A038290) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its shares pursuant to a trust contract with Samsung Securities Co., Ltd. The purpose of the share repurchase program is to stabilize the share price and increase shareholders value. The share repurchase program will continue until October 20, 2023. As of October 20, 2022, the company had 722,395 shares in treasury within scope available for dividend and had 1,851 shares in treasury through other repurchase.
Price Target Changed • Oct 14Price target decreased to ₩30,000Down from ₩40,000, the current price target is provided by 1 analyst. New target price is 68% above last closing price of ₩17,850. Stock is down 39% over the past year. The company is forecast to post earnings per share of ₩859 for next year compared to ₩114 last year.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Upcoming Dividend • Dec 22Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 25 April 2022. The company is not currently making a profit but it is cash flow positive. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.3%).
分析記事 • Apr 02Macrogen's (KOSDAQ:038290) Sluggish Earnings Might Be Just The Beginning Of Its ProblemsThe subdued market reaction suggests that Macrogen, Inc.'s ( KOSDAQ:038290 ) recent earnings didn't contain any...
分析記事 • Mar 03Macrogen (KOSDAQ:038290) Has Debt But No Earnings; Should You Worry?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Feb 18New 90-day high: ₩30,650The company is up 8.0% from its price of ₩28,400 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Jan 18New 90-day low: ₩25,450The company is down 12% from its price of ₩28,800 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 15% over the same period.
分析記事 • Jan 09Reflecting on Macrogen's (KOSDAQ:038290) Share Price Returns Over The Last Three YearsFor many investors, the main point of stock picking is to generate higher returns than the overall market. But if you...
Is New 90 Day High Low • Dec 23New 90-day low: ₩25,800The company is down 14% from its price of ₩29,900 on 24 September 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 14% over the same period.
Is New 90 Day High Low • Oct 15New 90-day low: ₩29,500The company is down 8.0% from its price of ₩31,900 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 1.0% over the same period.
お知らせ • Sep 24Macrogen Signs Export Agreement with LG InternationalMacrogen has established the first "Smart Mobile Lab" in Korea and has supplied it to Indonesia as well. Macrogen signed its first export agreement with LG International, on September 22nd. The initial two export units will be supplied to Indonesia through LG International. Following the first agreement, additional units are currently in last-minute negotiation over additional export agreements. Macrogen's Smart Mobile Lab is the mobile container type for on-site COVID 19 testing developed in Korea. It offers one-stop COVID-19 testing within a matter of minutes and it can be easily installed wherever as necessary. Macrogen has designed the SML that is easy to move and install in order to supply the K-quarantine packaging to overseas that are suffering from COVID-19 testing because of insufficient healthcare quarantine infrastructure. SML with strict Bio Safety Level-2(BSL-2) deals with all stages from viral RNA extraction, real-time polymerase chain reaction (RT-PCR), diagnosis, analysis, and to results. It also provides unique and differentiated services for Standard Operating Procedures (SOP), online/on-site training for lab technicians, and instrument maintenance. Macrogen's SML also displays excellent performance in terms of sustainability as it can be extended into a process capable of molecular diagnostic testing for various infectious diseases other than COVID-19. Currently, Macrogen is in the course of preparation for related patent applications based on the unique design structure of SML and the implementation of differentiated additional features.